1. Home
  2. IMMR vs MGNX Comparison

IMMR vs MGNX Comparison

Compare IMMR & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immersion Corporation

IMMR

Immersion Corporation

HOLD

Current Price

$6.48

Market Cap

207.5M

Sector

Technology

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$4.20

Market Cap

220.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMR
MGNX
Founded
1993
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
207.5M
220.6M
IPO Year
1999
2013

Fundamental Metrics

Financial Performance
Metric
IMMR
MGNX
Price
$6.48
$4.20
Analyst Decision
Strong Buy
Buy
Analyst Count
1
5
Target Price
$13.50
$5.00
AVG Volume (30 Days)
465.8K
1.3M
Earning Date
04-13-2026
05-08-2026
Dividend Yield
5.11%
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$35,013,000.00
$149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.19
P/E Ratio
$345.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.25
$1.19
52 Week High
$8.15
$4.64

Technical Indicators

Market Signals
Indicator
IMMR
MGNX
Relative Strength Index (RSI) 51.38 58.58
Support Level $6.33 $1.49
Resistance Level $6.88 $4.64
Average True Range (ATR) 0.23 0.30
MACD 0.03 -0.03
Stochastic Oscillator 44.84 60.50

Price Performance

Historical Comparison
IMMR
MGNX

About IMMR Immersion Corporation

Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: